Abstract
753 Background: The combination of doxorubicin and docetaxel (T) is highly effective in metastatic breast cancer. The non-pegylated liposomal formulation of doxorubicin Myocet (M) has been proven to be as effective as doxorubicin at same doses while reducing the cardiotoxicity and causing less myelosuppression and GI toxicity. The aim of this study was to evaluate the activity and tolerability of the combination of MT. Methods: M (60mg/m2) and T (75mg/m2) were administered at day 1 every 3 weeks for up to 8 cycles. To date 54 pts have been enrolled. 41 pts are evaluable for toxicity. A total of 208 cycles were given with a median of 6 (1–8). Main characteristics of pts: median age 57 yrs (37–70), median WHO PS 1 (0–2), anthracycline-pretreated 9 (22.0%), median number of metastases 2 (1–5). Results: Toxicity was mainly hematological with G3 or 4 neutropenia in 34,0% of cycles. Febrile neutropenia was encountered in 7,7%, G3 anemia in 4,4% and G3 platelets in 0.5%. Non hematological toxicities were general...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
